Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia

Gastrointestinal Cancer

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

Ann Oncol.

Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J

doi: 10.1093/annonc/mdy038.

Lung, Respiratory and Thoracic Cancer

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients

ESMO Open

Rothschild SI, Nachbur R, Herzog N, Passweg JR, Pless M

doi: 10.1016/j.esmoop.2020.100013

Genitourinary Cancer

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Eur J Cancer.

Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM

doi: 10.1016/j.ejca.2019.04.003.

Gastrointestinal Cancer

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Br J Cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D

doi: 10.1038/bjc.2016.185.

Genitourinary Cancer

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

Anticancer Res.

Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M

doi: 10.21873/anticanres.11480

Gastrointestinal Cancer

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

J Clin Oncol

Hecht JR, Lonardi S, Bendell J, Sim HW, Macarulla T, Lopez CD, Van Cutsem E, Muñoz Martin AJ, Park JO, Greil R, Wang H, Hozak RR, Gueorguieva I, Lin Y, Rao S, Ryoo BY

doi: 10.1200/JCO.20.02232

SPECIAL REPORT

Skin Cancer

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2

Lung, Respiratory and Thoracic Cancer

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Lancet Oncol.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV

doi: 10.1016/

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Cancer.

Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T

doi: 10.1002/cncr.30927.

Related content

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Bavencio® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma1,2

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Bavencio^® (Avelumab): Treatment for Metastatic Merkel Cell Carcinoma^1,2